Advanced Enzyme Technologies Ltd vs Iol Chemicals Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 347.95 as of 30 Apr 15:30 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2022 to 26.4 on March 2021 . This represents a CAGR of 0.00% over 5 yearsThe P/E Ratio of IOL Chemicals & Pharmaceuticals Ltd changed from 12.4 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3153 crore on March 2022 to ₹ 3852 crore on March 2021 . This represents a CAGR of 4.09% over 5 yearsThe Market Cap of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 2077 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 191.66 crore as compare to the Sep '25 revenue of ₹ 194.81 crore. This represent the decline of -1.62% The revenue of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 585.68 crore as compare to the Sep '25 revenue of ₹ 574.41 crore. This represent the growth of 1.96% The ebitda of Advanced Enzyme Technologies Ltd for the Dec '25 is ₹ 69.07 crore as compare to the Sep '25 ebitda of ₹ 70.34 crore. This represent the decline of -1.81% The ebitda of IOL Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 51.36 crore as compare to the Sep '25 ebitda of ₹ 63.96 crore. This represent the decline of -19.7% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 43.18 crore over 7 quarters. This represents a CAGR of 12.79% The net profit of IOL Chemicals & Pharmaceuticals Ltd changed from ₹ 29.97 crore to ₹ 20.58 crore over 7 quarters. This represents a CAGR of -19.33% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of IOL Chemicals & Pharmaceuticals Ltd changed from 7.92 % on March 2021 to 23.25 % on March 2025 . This represents a CAGR of 24.03% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About IOL Chemicals & Pharmaceuticals Ltd

IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active Pharmaceutical Ingredient (API) and specialty chemicals sectors.
Its extensive expertise in both API and specialty chemicals strengthens the business model and opens doors to diversified growth opportunities. Within the API segment, IOL develops and supplies a wide range of essential products utilized by pharmaceutical companies worldwide for the production of key medicines.
It serves as a global supplier of various APIs, including Ibuprofen, Metformin, Clopidogrel, Lamotrigine, Pantoprazole, and Fenofibrate, alongside other APIs, and maintains a significant presence in all major therapeutic categories. In the Specialty Chemicals division, IOL manufactures Ethyl Acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid (MCA), and Acetyl Chloride.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and IOL Chemicals & Pharmaceuticals Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or IOL Chemicals & Pharmaceuticals Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 3,894 Cr while Market cap of IOL Chemicals & Pharmaceuticals Ltd is 2,765 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and IOL Chemicals & Pharmaceuticals Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and IOL Chemicals & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and IOL Chemicals & Pharmaceuticals Ltd?

As of May 3, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹347.95. On the other hand, IOL Chemicals & Pharmaceuticals Ltd stock price is INR ₹94.2.

How do dividend payouts of Advanced Enzyme Technologies Ltd and IOL Chemicals & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and IOL Chemicals & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.